183
Participants
Start Date
December 20, 2006
Primary Completion Date
June 9, 2010
Study Completion Date
June 9, 2010
Voreloxin Injection
All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
Medstar Research Institute at Washington Hospital Center, Washington D.C.
Memorial Sloan Kettering Cancer Center (MSKCC), New York
University of Pittsburgh Medical Center at Magee-Womens Hospital, Pittsburgh
The Harry and Jeanette Weinberg Institute at Franklin Square, Baltimore
Hall and Martin, MD's, P.C., Knoxville
Louisville Oncology Clinical Research Program, Louisville
Oncology Specialists, S.C. at Luthern General Advanced Care Center, Park Ridge
Premiere Oncology of Arizona, Scottsdale
Sharp Clinical Oncology Research, San Diego
Gynecologic Oncology Associates, Newport Beach
Stanford University, Stanford
Kaiser Permanente NW Region, Portland
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
Tom Baker Cancer Centre, Calgary
BC Cancer Agency at Centre for Southern Interior, Kelowna
BC Cancer Agency at Fraser Valley Centre, Surrey
BC Cancer Agency at Vancouver, Vancouver
BC Cancer Agency - Vancouver Island Centre, Victoria
Juravinski Cancer Centre Department of Oncology, Hamilton
Lead Sponsor
Sunesis Pharmaceuticals
INDUSTRY